Premium
SCAI statement on drug‐eluting stents: Practice and health care delivery implications
Author(s) -
Hodgson John McB.,
King Spencer B.,
Feldman Ted,
Cowley Michael J.,
Klein Lloyd W.,
Babb Joseph D.
Publication year - 2003
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.10513
Subject(s) - medicine , statement (logic) , drug , drug eluting stent , intensive care medicine , stent , pharmacology , restenosis , political science , law
Coronary artery disease remains a major health problem throughout the world. Since the inception of percutaneous transluminal coronary angioplasty in 1978 and the addition of stents in the early 1990s, much progress has been made in the treatment of atherosclerotic obstructive coronary artery disease. Percutaneous coronary intervention (PCI) has eclipsed coronary artery bypass grafting surgery as the treatment of choice for many patients with obstructive coronary lesions. PCI, however, has been limited by restenosis, the incidence of which is highly variable, ranging from less than 5% to over 50% in certain clinical and anatomic subgroups. While restenosis rates have fallen consistently over the past 10 years due to stent use, ancillary guidance techniques, and possibly adjunctive pharmacology, the recent development of antiproliferative drug-eluting stents (DES) is a major breakthrough in preventing restenosis after initial PCI. The use of DES in the treatment of obstructive coronary disease will have major beneficial medical impact on the care of patients, but also will create additional medicolegal, financial, and programmatic ramifications. This statement will provide a preliminary framework to address the multifactorial issues surrounding the introduction of DES into widespread practice.